AFT Forsyth & Company’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$700K Buy
4,147
+1
+0% +$171 0.33% 64
2025
Q4
$700K Sell
4,146
-17
-0.4% -$2.76K 0.3% 65
2025
Q3
$601K Sell
4,163
-43
-1% -$5.87K 0.29% 65
2025
Q2
$532K Sell
4,206
-5
-0.1% -$614 0.27% 66
2025
Q1
$539K Buy
4,211
+2
+0% +$271 0.29% 74
2024
Q4
$556K Sell
4,209
-153
-4% -$21.5K 0.27% 76
2024
Q3
$635K Sell
4,362
-32
-0.7% -$4.63K 0.31% 71
2024
Q2
$603K Buy
4,394
+30
+0.7% +$4K 0.3% 76
2024
Q1
$599K Buy
4,364
+108
+3% +$14.7K 0.34% 71
2023
Q4
$578K Sell
4,256
-387
-8% -$47.2K 0.36% 71
2023
Q3
$568K Sell
4,643
-5
-0.1% -$636 0.42% 64
2023
Q2
$590K Sell
4,648
-385
-8% -$50K 0.42% 65
2023
Q1
$650K Buy
5,033
+56
+1% +$7.33K 0.5% 60
2022
Q4
$653K Buy
4,977
+141
+3% +$18.2K 0.56% 57
2022
Q3
$566K Buy
4,836
+115
+2% +$14.3K 0.51% 59
2022
Q2
$555K Buy
4,721
+1
+0% +$119 0.45% 64
2022
Q1
$615K Sell
4,720
-68
-1% -$8.86K 0.39% 71
2021
Q4
$731K Buy
4,788
+31
+0.7% +$4.8K 0.38% 80
2021
Q3
$769K Buy
4,757
+60
+1% +$10.1K 0.41% 73
2021
Q2
$769K Buy
4,697
+65
+1% +$10K 0.41% 83
2021
Q1
$697K Buy
4,632
+30
+0.7% +$4.76K 0.42% 83
2020
Q4
$697K Buy
4,602
+95
+2% +$13.6K 0.44% 81
2020
Q3
$610K Buy
4,507
+331
+8% +$44.9K 0.45% 70
2020
Q2
$571K Buy
4,176
+75
+2% +$9.56K 0.48% 69
2020
Q1
$442K Sell
4,101
-53
-1% -$6.1K 0.44% 76
2019
Q4
$501K Buy
4,154
+125
+3% +$13.9K 0.38% 87
2019
Q3
$401K Sell
4,029
-120
-3% -$12.6K 0.33% 99
2019
Q2
$453K Hold
4,149
0.37% 88
2019
Q1
$464K Hold
4,149
0.4% 89
2018
Q4
$400K Sell
4,149
-90
-2% -$9.55K 0.4% 88
2018
Q3
$517K Hold
4,239
0.43% 85
2018
Q2
$466K Sell
4,239
-90
-2% -$9.63K 0.41% 90
2018
Q1
$462K Hold
4,329
0.43% 85
2017
Q4
$462K Buy
+4,329
New +$463K 0.45% 76
2013
Q3
$132K Buy
1,884
+744
+65% +$48.7K 0.17% 126
2013
Q2
$66K Buy
+1,140
New +$65.9K 0.09% 148

Other funds holding IBB

AFT Forsyth & Company's IBB Position: Q1 2026 in Review

AFT Forsyth & Company increased its iShares Biotechnology ETF (IBB) stake by 0.02% in Q1 2026, buying an estimated $171 and bringing the position to 4,147 shares worth $700K. The position accounts for 0.33% of the portfolio, ranked #64.

AFT Forsyth & Company first reported a position in IBB in Q2 2013 and has held it in 36 quarters since. The position peaked at $769K in Q3 2021. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • AFT Forsyth & Company held 4,147 shares of iShares Biotechnology ETF worth $700K as of Q1 2026.
  • AFT Forsyth & Company bought 1 iShares Biotechnology ETF share in Q1 2026, an estimated $171.
  • iShares Biotechnology ETF made up 0.33% of AFT Forsyth & Company's portfolio in Q1 2026, its #64 holding.
  • AFT Forsyth & Company first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 36 quarters since.
  • AFT Forsyth & Company's iShares Biotechnology ETF position peaked at $769K in Q3 2021.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on AFT Forsyth & Company's 13F filing for Q1 2026, filed 14 May 2026.